Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

<p>Introduction: IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Masatoshi Kudo, Tatsuya Yamashita, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take, Kyoko Yamada, Yuki Nakagawa, Hayato Takahashi, Masafumi Ikeda
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2025-01-01
Colecção:	Liver Cancer
Acesso em linha:	https://karger.com/article/doi/10.1159/000544981
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!